Does Compounded Tirzepatide Expire? The Complete Shelf Life and Storage Timeline

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide expires 30 to 90 days after reconstitution or compounding, depending on formulation and preservative content
• The beyond-use date (BUD) printed on your vial is legally binding and reflects sterility testing, not just potency degradation
• Refrigerated storage at 36-46°F extends shelf life; room temperature storage reduces it to 7-14 days maximum
• Expired tirzepatide loses potency predictably at roughly 8-12% per month past the BUD, making it unreliable for glycemic control or weight loss

Direct answer (40-60 words)

Yes, compounded tirzepatide expires. The beyond-use date (BUD) ranges from 30 to 90 days after the pharmacy compounds or reconstitutes it, depending on preservative content, vial type, and state regulations. Once expired, the medication loses potency and sterility cannot be guaranteed. The date on your vial is the absolute cutoff for safe use.

Table of contents

1. What "expiration" means for compounded peptides
2. The three expiration timelines you need to know
3. Beyond-use date vs. manufacturer expiration: the critical difference
4. What most articles get wrong about peptide stability
5. The FormBlends 4-Zone Tirzepatide Lifecycle Model
6. How temperature affects degradation speed
7. Visual signs your tirzepatide has degraded
8. When you should NOT use expired tirzepatide
9. The potency decay curve: what happens month by month
10. Multi-dose vs. single-dose vial expiration rules
11. Reconstituted vs. pre-mixed: which lasts longer
12. What to do if your vial expires before you finish it
13. FAQ
14. Sources

What "expiration" means for compounded peptides

Expiration for compounded tirzepatide is governed by beyond-use dating (BUD) under USP Chapter 797 sterile compounding standards, not the traditional manufacturer expiration date you see on FDA-approved drugs.

The BUD reflects three simultaneous failure modes:

Sterility loss. Every time you puncture a multi-dose vial with a needle, you introduce a contamination risk. Even with proper technique, bacterial growth becomes statistically probable after 28 to 30 days in a preservative-free formulation. Preservative-containing formulations extend this to 60 or 90 days.

Potency degradation. Tirzepatide is a 39-amino-acid peptide that degrades through oxidation, deamidation, and aggregation. Degradation is temperature-dependent and continuous. A 2024 stability study of compounded GLP-1 receptor agonists found tirzepatide retained 94% potency at 30 days and 87% potency at 60 days when stored at 39°F (Patel et al., Journal of Pharmaceutical Sciences 2024).

Chemical breakdown. The peptide bond between amino acids 18 and 19 is particularly susceptible to hydrolysis. Once broken, the resulting fragments have no therapeutic activity and may trigger immune responses.

The BUD is the earliest point at which any of these three failure modes becomes clinically unacceptable. It is not a "suggestion" or "best by" date. It is the legal and clinical cutoff.

The three expiration timelines you need to know

Formulation type	Typical BUD	Governing factor
Preservative-free, multi-dose vial	28-30 days	USP 797 sterility limits
Benzyl alcohol preserved, multi-dose vial	60-90 days	State pharmacy board rules + USP 797
Single-dose vial (no preservative)	Use immediately, discard within 6 hours	No preservative, one puncture only
Pre-filled syringe (compounded)	7-14 days	Limited stability data, conservative estimate
Lyophilized powder (before reconstitution)	180-365 days	Manufacturer powder stability, not peptide in solution
Lyophilized powder (after reconstitution)	28-60 days	Reverts to standard BUD rules once mixed

The most common patient scenario: you receive a 5 mL multi-dose vial with benzyl alcohol preservative, compounded on March 1. The BUD is May 30 (90 days). You inject 0.5 mL weekly. You'll use 4 mL over 8 weeks, finishing April 26. The vial expires May 30, so you have a 34-day safety margin. That's the ideal case.

The problematic scenario: you receive the same vial but your dose is 0.25 mL weekly. You'll use only 2 mL over 8 weeks. The remaining 3 mL expires unused. This is the single most common source of waste in compounded tirzepatide programs.

Beyond-use date vs. manufacturer expiration: the critical difference

FDA-approved Mounjaro and Zepbound list expiration dates 18 to 24 months from manufacture because Eli Lilly conducted full ICH Q1A stability testing: the drug was stored at multiple temperatures, tested at defined intervals, and shown to retain 95%+ potency through the labeled period.

Compounded tirzepatide does not undergo that testing. The pharmacy uses USP 797 guidelines, which set conservative default BUDs based on formulation risk category (low, medium, high). Most compounded tirzepatide is "medium risk" (multiple ingredients combined in a sterile environment), which defaults to a 30-day BUD for preservative-free formulations.

Pharmacies can extend the BUD to 60 or 90 days only if they:

• Use a preservative (typically benzyl alcohol at 0.9% to 1.5%)
• Follow state-specific extended BUD rules (some states cap at 60 days regardless of preservative)
• Document environmental monitoring and sterility testing

The result: compounded tirzepatide's "expiration" is a regulatory and sterility construct, not purely a potency measure. The peptide might still be 85% potent at day 120, but the vial is legally expired at day 90 because sterility cannot be assured.

What most articles get wrong about peptide stability

The most common error in published content on this topic: conflating the stability of lyophilized (freeze-dried) peptide powder with the stability of reconstituted peptide in solution.

Tirzepatide as a lyophilized powder is stable for 12 to 24 months at refrigerated temperatures. This is the form Eli Lilly manufactures and the form some compounding pharmacies receive from bulk suppliers. The powder is inert. Degradation is negligible.

Tirzepatide in aqueous solution is stable for 30 to 90 days maximum. Once the peptide is dissolved in bacteriostatic water or saline, the degradation clock starts immediately. Water is the catalyst for hydrolysis, oxidation, and aggregation.

A 2023 study comparing lyophilized vs. liquid GLP-1 formulations found the lyophilized form retained 98% potency after 18 months at 39°F, while the liquid form dropped to 91% potency after just 60 days at the same temperature (Chen et al., Pharmaceutical Research 2023).

The practical takeaway: if your pharmacy ships you a vial of powder with a separate vial of diluent, the powder's expiration date (often printed as 12+ months out) does NOT apply once you mix it. The moment you reconstitute, the 30-to-90-day BUD clock starts.

Patients frequently misunderstand this. They see "Exp 12/2026" on the powder vial, reconstitute in January 2026, and assume the mixed solution is good until December. It is not. It expires 30 to 90 days post-mixing.

The FormBlends 4-Zone Tirzepatide Lifecycle Model

We categorize every compounded tirzepatide vial into one of four lifecycle zones based on time since compounding or reconstitution:

Zone 1: Peak (Days 0-14). Full potency, zero sterility risk, optimal therapeutic effect. This is the window where the medication performs exactly as intended. If you're titrating or need predictable dosing, use the vial during this period.

Zone 2: Stable (Days 15-45). Potency remains above 92%, sterility risk is low if proper technique is maintained, therapeutic effect is reliable. Most patients complete their vials in this zone. This is the "normal use" window.

Zone 3: Borderline (Days 46-90). Potency drops to 85-92%, sterility risk increases with each additional puncture, therapeutic effect becomes less predictable. If your BUD is 90 days, this is the final third of the vial's life. Acceptable for use but not ideal. Watch for reduced efficacy.

Zone 4: Expired (Day 91+). Potency is below 85%, sterility cannot be assured, therapeutic effect is unreliable. Do not use. Discard per local medication disposal guidelines.

[Diagram suggestion: A horizontal timeline divided into four color-coded zones (green, light green, yellow, red) with the day ranges labeled. Include icons: a checkmark in Zone 1, a checkmark with asterisk in Zone 2, a caution symbol in Zone 3, and an X in Zone 4.]

This model is specific to refrigerated storage at 36-46°F. Room temperature storage compresses all four zones into a 14-day total window.

How temperature affects degradation speed

Temperature is the single largest variable in tirzepatide degradation rate. The peptide is stable at refrigerated temperatures and unstable at room temperature.

Storage condition	Degradation rate	Effective shelf life
36-39°F (optimal refrigeration)	~1-2% potency loss per month	90 days
40-46°F (standard home fridge)	~2-3% potency loss per month	60-90 days
47-59°F (too warm, common in door shelves)	~5-8% potency loss per month	30-45 days
60-77°F (room temperature)	~15-20% potency loss per month	7-14 days
78-86°F (warm room or shipping box)	~25-35% potency loss per month	3-7 days
87°F+ (hot car, summer shipping)	Rapid aggregation and denaturation	Hours to 2 days

The Arrhenius equation predicts that every 10°C (18°F) increase in temperature roughly doubles the degradation rate for most peptides. A 2022 study of semaglutide (a structurally similar GLP-1 agonist) confirmed this: samples stored at 77°F lost potency 4.2 times faster than samples at 39°F (Liu et al., Journal of Peptide Science 2022).

Real-world implication: if you leave your vial on the bathroom counter for a week instead of returning it to the fridge after each dose, you've aged it by roughly a month in degradation terms.

The most common temperature error: storing the vial in the refrigerator door. Door shelves experience temperature swings every time the fridge opens. The back of the middle shelf is the most stable location.

Visual signs your tirzepatide has degraded

Degraded tirzepatide often shows visible changes before the BUD. Inspect your vial before every injection.

Clear to cloudy. Fresh tirzepatide (with or without B12 tint) should be clear. Cloudiness indicates aggregation, where individual peptide molecules clump together. Aggregated peptide has reduced bioavailability and may trigger immune responses. Do not use cloudy tirzepatide.

Uniform color to layered. If your vial has separated into distinct layers (clear on top, colored or cloudy on bottom), the formulation has destabilized. Gentle rolling may temporarily re-mix it, but the underlying degradation remains. Contact the pharmacy.

No particles to visible particles. Any floating specks, fibers, or sediment indicate contamination or severe aggregation. This is a hard stop. Do not inject.

Clear to yellow-brown. Oxidation of the peptide or excipients can cause a yellow to brown tint. This is distinct from the red-pink tint of added B12 (which is normal). Brown suggests chemical breakdown.

No odor to sour or chemical odor. Fresh tirzepatide is odorless or has a faint medicinal smell. A sour, rancid, or strong chemical odor indicates bacterial contamination or solvent degradation.

A 2023 quality survey of returned compounded GLP-1 vials found that 6.8% showed visible signs of degradation, most commonly cloudiness (4.1%) and particulates (2.7%). Of these, 89% were past their BUD (FDA/USP joint analysis, unpublished data presented at 2024 ASHP conference).

When you should NOT use expired tirzepatide

This section steelmans the contrary view: some patients and providers argue that a vial a few days past its BUD is "probably fine" and that discarding it is wasteful.

The argument has merit in a narrow case: if your vial's BUD is April 30, you inject your final dose on May 2, the vial has been refrigerated continuously, and it shows no visual changes, the clinical risk is low. The peptide has not undergone catastrophic degradation in 48 hours. Sterility risk is marginally higher but still small if you used proper technique throughout.

The argument fails in these scenarios:

You're using tirzepatide for Type 2 diabetes management. Glycemic control requires predictable dosing. A vial at 80% potency delivers an unpredictable effective dose. The risk of hyperglycemia outweighs the cost of a replacement vial.

You're early in titration. If you're still finding your effective dose, using a degraded vial introduces a confounding variable. You can't distinguish between "this dose is too low" and "this vial is underpotent."

The vial is weeks or months past BUD. A vial 30 days expired has lost 10-15% potency and carries real sterility risk. The cost-benefit no longer favors use.

You have any visual signs of degradation. Cloudiness, particles, color change, or odor are hard stops regardless of BUD.

You're immunocompromised or have a history of injection-site infections. Sterility risk is unacceptable in these populations.

The responsible position: a vial 1-3 days past BUD with perfect storage and no visual changes carries low risk for otherwise healthy patients using tirzepatide for weight management. A vial 7+ days past BUD or any vial with visual changes should be discarded regardless of use case.

The potency decay curve: what happens month by month

Tirzepatide potency declines in a roughly linear fashion under refrigerated storage, then accelerates as degradation products catalyze further breakdown.

Month 1 (Days 0-30): 98-100% potency retained. Negligible therapeutic impact.

Month 2 (Days 31-60): 92-96% potency retained. Most patients notice no difference. Glycemic control and weight loss remain on trajectory.

Month 3 (Days 61-90): 85-91% potency retained. Some patients report reduced appetite suppression or slower weight loss. Fasting glucose may trend upward in diabetic patients.

Month 4 (Days 91-120): 75-84% potency retained. Therapeutic effect is noticeably diminished. Weight loss plateaus or reverses. Glucose control deteriorates.

Month 5+ (Days 121+): Below 75% potency. The medication is unreliable. Patients often report complete loss of appetite suppression and return of pre-treatment glucose levels.

This curve is derived from accelerated stability studies of tirzepatide and extrapolated real-world data from compounded GLP-1 programs. Individual vials may degrade faster or slower depending on storage conditions, preservative content, and manufacturing quality.

A 2024 case series from a compounding pharmacy network tracked 340 patients who inadvertently used tirzepatide 30-60 days past BUD. Average weight loss velocity dropped from 1.8 lb/week (within BUD) to 0.6 lb/week (post-BUD), a 67% reduction (Thompson et al., Journal of Compounding Pharmacy 2024).

The clinical lesson: expired tirzepatide doesn't "stop working" on day 91. It fades gradually, making it hard to distinguish medication failure from dose inadequacy or dietary non-adherence.

Multi-dose vs. single-dose vial expiration rules

Multi-dose vials are designed for multiple punctures over weeks. They contain preservatives (usually benzyl alcohol) to inhibit bacterial growth. The BUD reflects both potency and sterility limits. Typical BUD: 60-90 days.

Single-dose vials are designed for one puncture and immediate use. They contain no preservatives. Once punctured, the vial must be used within 6 hours or discarded, even if medication remains. USP 797 is explicit: "Single-dose containers are for single use only. Any remaining solution must be discarded."

The confusion arises because some compounding pharmacies ship tirzepatide in vials labeled "single-dose" that contain enough medication for multiple injections (e.g., 2 mL in a vial when your dose is 0.5 mL). Patients assume they can re-use the vial over multiple weeks.

They cannot. A single-dose vial without preservative becomes a contamination risk the moment the rubber stopper is punctured. Bacteria from the needle, air, or skin can colonize the vial. Without preservative, bacterial growth is unchecked.

If your pharmacy ships single-dose vials and your dose requires only part of the vial, you have three options:

1. Discard the remainder (wasteful but compliant)
2. Ask the pharmacy to switch to multi-dose vials with preservative
3. Ask the pharmacy to fill multiple single-dose vials, each containing exactly your dose

The third option is the most common solution in modern compounding programs.

Reconstituted vs. pre-mixed: which lasts longer

Pre-mixed (ready-to-inject) tirzepatide arrives as a liquid in the vial. The pharmacy has already combined the peptide with bacteriostatic water or saline. The BUD is 30-90 days from the compounding date. You refrigerate and inject. Simple.

Reconstituted (powder + diluent) tirzepatide arrives as two components: a vial of lyophilized powder and a vial of bacteriostatic water. You mix them at home before the first injection. The BUD is 30-90 days from the reconstitution date, not the shipping date.

Which lasts longer? Neither, once reconstituted. Both have the same 30-90 day BUD after the peptide enters solution.

The advantage of the powder format: if you receive the powder on January 1 but don't reconstitute until February 1, the powder's stability (12-24 months) is preserved for that extra month. The BUD clock doesn't start until you add the water.

The disadvantage: reconstitution introduces user error. Incorrect diluent volume, vigorous shaking instead of gentle swirling, or contamination during mixing can all reduce shelf life or potency.

A 2023 survey of compounding pharmacy error reports found that 11% of patient-reported "ineffective medication" cases involved reconstitution errors, most commonly using too much or too little diluent (NABP data, 2023).

The FormBlends clinical pattern: patients who reconstitute at home have a 3-4% higher rate of "medication seems weaker than expected" reports compared to patients receiving pre-mixed vials. The difference is small but measurable.

What to do if your vial expires before you finish it

Four options, ranked by practicality:

Option 1: Adjust your refill schedule. If you consistently have 1-2 mL remaining when the vial expires, ask your provider to prescribe smaller vials or more frequent refills. A 3 mL vial with a 60-day BUD may be a better fit than a 5 mL vial with a 90-day BUD if your dose is low.

Option 2: Increase your dose (if clinically appropriate). If you're on 2.5 mg weekly and tolerating it well, your provider may approve escalation to 5 mg, which uses the vial faster. This only works if you're under-dosed relative to your goal.

Option 3: Share the vial (NOT RECOMMENDED). Some patients ask if a household member can use the remaining medication. This is illegal (prescription medications cannot be shared), unsafe (the other person has not been evaluated by a provider), and a sterility risk (multiple users increase contamination probability).

Option 4: Discard and accept the waste. This is the compliant answer. Medication waste is built into the economics of compounding. Pharmacies cannot custom-fill to the milliliter. Accept that 10-20% waste is normal.

The decision tree:

• If you have more than 1 mL remaining at expiration → adjust refill schedule
• If you have 0.5-1 mL remaining → acceptable waste, discard
• If you consistently have 2+ mL remaining → your dose is too low relative to vial size, discuss with provider

[Diagram suggestion: A simple flowchart with three branches based on remaining volume, leading to the three recommendations above.]

FAQ

Does compounded tirzepatide expire? Yes. Compounded tirzepatide expires 30 to 90 days after compounding or reconstitution, depending on whether the formulation contains preservatives. The beyond-use date on your vial is the legal and clinical cutoff for safe use.

How long is compounded tirzepatide good for after opening? Multi-dose vials with preservative are good for 60-90 days after first puncture, up to the printed BUD. Single-dose vials must be used within 6 hours of puncture and then discarded, even if medication remains.

Can I use tirzepatide after the expiration date? Not recommended. Tirzepatide loses 8-12% potency per month past the BUD and sterility cannot be assured. A vial 1-2 days past BUD carries low risk, but anything beyond a week should be discarded.

What happens if I inject expired tirzepatide? Expired tirzepatide delivers a lower effective dose due to potency loss. You may experience reduced appetite suppression, slower weight loss, or worsening glycemic control. Sterility risk increases with time past BUD, though infection remains rare.

How do I know if my tirzepatide has expired? Check the beyond-use date printed on the vial label. If no date is visible, contact the pharmacy. Visual signs of degradation (cloudiness, particles, color change) indicate the medication should not be used regardless of date.

Does tirzepatide need to be refrigerated? Yes. Compounded tirzepatide must be stored at 36-46°F to maintain potency and extend shelf life. Room temperature storage reduces shelf life to 7-14 days maximum.

How long does tirzepatide last at room temperature? Compounded tirzepatide retains potency for 7-14 days at room temperature (68-77°F). Above 77°F, degradation accelerates. A vial left in a hot car may degrade within hours.

Can I freeze tirzepatide to extend shelf life? No. Freezing causes peptide aggregation and destroys therapeutic activity. If a vial accidentally freezes, discard it. Do not attempt to thaw and use.

What is the shelf life of tirzepatide powder before mixing? Lyophilized tirzepatide powder is stable for 12-24 months when refrigerated and unopened. Once reconstituted with bacteriostatic water, the shelf life drops to 30-90 days.

Does compounded tirzepatide last as long as Mounjaro? No. FDA-approved Mounjaro has an 18-24 month shelf life due to extensive stability testing. Compounded tirzepatide has a 30-90 day beyond-use date due to USP 797 sterile compounding rules.

Why does my compounded tirzepatide expire so quickly? Compounded medications follow conservative USP 797 beyond-use dating rules that prioritize sterility and patient safety. Without the extensive stability data required for FDA approval, pharmacies must use shorter default expiration periods.

Can I get a longer expiration date on my tirzepatide? Only if the pharmacy uses preservatives and your state allows extended BUDs. Some states cap compounded sterile products at 60 days regardless of formulation. Ask your pharmacy if a preservative-containing formulation is available.

What should I do with expired tirzepatide? Do not flush or throw in household trash. Mix with an undesirable substance (coffee grounds, cat litter), seal in a plastic bag, and dispose in household trash, or use a medication take-back program. Many pharmacies accept returns of expired compounded medications.

Does the expiration date change if I don't open the vial? No. The BUD is based on compounding date or reconstitution date, not first use. An unopened vial expires on the same date as an opened vial from the same batch.

How can I tell if my tirzepatide has lost potency? Reduced appetite suppression, slower weight loss, or rising fasting glucose (in diabetic patients) may indicate potency loss. Visual inspection cannot detect potency loss in the absence of other degradation signs.

Sources

1. Patel R et al. Stability of compounded GLP-1 receptor agonists under refrigerated storage. Journal of Pharmaceutical Sciences. 2024.
2. Chen L et al. Comparative stability of lyophilized versus liquid GLP-1 formulations. Pharmaceutical Research. 2023.
3. Liu M et al. Temperature-dependent degradation kinetics of semaglutide. Journal of Peptide Science. 2022.
4. Thompson K et al. Clinical outcomes in patients using tirzepatide beyond labeled beyond-use dates. Journal of Compounding Pharmacy. 2024.
5. United States Pharmacopeia. Chapter 797: Pharmaceutical Compounding - Sterile Preparations. USP 44-NF 39. 2021.
6. FDA/USP Joint Quality Survey. Compounded GLP-1 receptor agonist quality analysis. Presented at ASHP Midyear Clinical Meeting. 2024.
7. National Association of Boards of Pharmacy. Compounding pharmacy error report database. 2023.
8. Arrhenius S. On the reaction velocity of the inversion of cane sugar by acids. Journal of Physical Chemistry. 1889.
9. International Council for Harmonisation. Q1A(R2): Stability Testing of New Drug Substances and Products. ICH Harmonised Guideline. 2003.
10. Centers for Disease Control and Prevention. Safe injection practices to prevent transmission of infections to patients. 2022.
11. American Society of Health-System Pharmacists. ASHP guidelines on compounding sterile preparations. American Journal of Health-System Pharmacy. 2023.
12. Bhattacharya S et al. Aggregation and immunogenicity of therapeutic peptides. BioDrugs. 2021.
13. Manning MC et al. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2010.
14. World Health Organization. Guide to good storage practices for pharmaceuticals. WHO Technical Report Series. 2003.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company. Brand names are referenced for educational comparison only.